Erwin G. Van Meir, PhD
- Referred Journals
- Review Articles
- Symposium Contributions
- Books and Chapters
- Other Publications
- Media Relations
- Research
Erwin G. Van Meir, PhD is a Professor of Neurosurgery and Hematology/ Oncology at the Emory University School of Medicine and Director of the Winship Cancer Institute's Brain Tumor Program and Laboratory of Molecular Neuro-Oncology part of a multidisciplinary neuro-oncology team aimed at designing new approaches for brain tumor therapy. Dr. Van Meir has extensive experience in cancer research. He was trained in molecular biology at the Universities of Fribourg and Lausanne, Switzerland where he obtained his PhD in 1989. Dr. Van Meir pursued postdoctoral work at the Ludwig Institute for Cancer Research in San Diego, joining the Faculty of Emory University in 1998.
Dr. Van Meir and his colleagues have made many original contributions to cancer research, primarily directed at defining the genetic alterations in brain tumors and determining their biological significance for tumor development, with particular emphasis on angiogenesis and hypoxia, and translating this knowledge into new therapeutic approaches.
Dr. Van Meir's primary research interests include brain tumor biology and genetics. He has authored over 100 scientific publications on this topic, serves as a reviewer for over 30 international cancer research journals, is a current member of the editorial board of Frontiers in Bioscience, Neuro-Oncology and International Journal of Oncology, and is a former associate editor for the International Journal of Cancer. He has trained multiple undergraduate and graduate students, medical fellows and postdocs and is a member of the Graduate Division of Biological and Biochemical Sciences at Emory, where he participates in the programs in Genetics and Molecular Biology and in Biochemistry, Cell and Developmental Biology. Dr. Van Meir is active in several scientific societies, including the American Society for Neuro-Oncology and the European Association for Neuro-Oncology. His research, supported by the NIH, the SNSF and many private foundations, is described in more than 100 peer-reviewed international scientific publications that have cumulated over 3,000 citations. Dr. Van Meir is also the author of several US and foreign patents. His contributions have been presented in over 100 invited seminars worldwide and have furthered the understanding of brain tumor biology and genetics, as well as led to the development novel preclinical therapeutic approaches.
(Below publications are a select list from post-2000)
Referred Journals
Kessler R., Hamou M-F., Albertoni M., de Tribolet N., Arand M. and Van Meir, E.G. (2000). Identification of the putative brain tumor antigen BF7/GE2 as the (de)toxifying enzyme microsomal epoxide hydrolase. Cancer Res. 60, 1403-1409
Tenan, M., Fulci, G., Albertoni, M., Diserens, A-C., Hamou M-F, El-Atifi-Borel M., Feige, J-J., Pepper, M., and Van Meir, E.G. (2000). Thrombospondin-l is downregulated by hypoxia and suppresses tumorigenicity in human glioblastoma cells. J. Exp. Med. 191, 1789-1798
Fulci, G., Labuhn, M., Maier, D., Lachat, Y., Hausmann, O., Hegi, M.E., Janzer, R.C., Merlo, A. and Van Meir, E.G. (2000). p53 gene mutation and p14Arf deletion are two mutually exclusive events in human glioblastoma. Oncogene 19, 3816-3822
Hao, C., Beguinot F, Condorelli G, Trencia A, Van Meir EG, Yong VW, Parney IF, Roa WH, Petruk KC (2001). Induction and intracellular regulation of TRAIL-induced apoptosis in human malignant glioma cells. Cancer Res. 61, 1162-1170
Labuhn M, Jones G, Speel EJM, Maier D, Zweifel D, Gratzl O, Van Meir EG, Hegi ME, Merlo A (2001). Quantitative real-time PCR does not show selective targeting of p14ARF but concomitant inactivation of both p16INK and p14ARF in 105 human primary gliomas. Oncogene, 20, 1103-1109
Cavallaro U, Tenan M, Castelli V, Perilli A, Maggiano N, Van Meir EG, Montesano R, Soria MR and Pepper M (2001). Response of bovine endothelial cells to FGF-2 and VEGF is dependent on their site of origin: relevance to the regulation of angiogenesis. J. Cell. Bioch. 82, 619-633.
Cheng G, Cao Z, Xu X, Van Meir EG and Lambeth JD (2001). Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4 and Nox5. Gene 269, 131-140.
Ikeda J, Tada M, Ishii N, Saya N, Tsuchiya K, Okaichi K, Mishima K, Fulci G, Van Meir EG (2001). Restoration of wild type p53 activity in a glioblastoma cell line with intrinsic temperature-sensitive p53 induces growth arrest but not apoptosis. Int. J. Cancer 94, 35-43
Post DE and Van Meir EG (2001). Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Therapy 8, 1801-1807
Kragh M, Quistorff B, Tenan M, Van Meir EG and Kristjansen PEG (2002). Overexpression of thrombospondin-1 reduces vascularity but not perfusion in glioblastoma. Cancer Res 62, 1191-1195
Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW and Zhong H (2002). Geldanamycin induces degradation of hypoxia-inducible factor 1a protein via the proteosome pathway in prostate cancer cells. Cancer Res 62, 2478-2482
Fulci, G, Ishii N, Maurici D, Gernert K, Hainaut P, Kaur B and Van Meir EG (2002). Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germline mutation: evidence for a precursor lesion. Cancer Res. 62, 2897-2906 (selected for journal cover)(comment in Cell Death &Differentiation)
Albertoni M, Shaw PH, Nozaki M, Godard S, Tenan M, Hamou MF, Fairlie DW, Breit SN, Paralkar VM, de Tribolet N, Van Meir EG, Hegi ME (2002). Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene 21, 4212-4219
Bratt A, Wilson WJ, Troyanovsky B, Aase K, Kessler R, Van Meir EG and Holmgren L (2002). Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains. Gene 298, 69-77
Kaur B, Brat D, Calkins CC, and Van Meir EG (2003). Brain Angiogenesis Inhibitor 1 (BAI1) is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am J Pathol 162, 19-27
Post DE and Van Meir EG (2003). A novel Hypoxia Inducible Factor activated oncolytic adenovirus for cancer therapy. Oncogene 22, 2065-72
Song JH, Song DK, Pyrzynska B, Petruk KC, Van Meir EG and Hao C (2003). TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways. Brain Pathol 13, 539-553
Kim EL, Yoshizato K, Meissner H, Zapf S, Nüsing RM, Yamamoto H, Van Meir EG, Deppert W and Giese A (2003). Tumor suppressor p53 inhibits transcriptional activation of the invasion gene thromboxane synthse mediated by the protooncogenic factor Ets-1. Oncogene 22, 7716-27
Cobbs CS, Whisenhunt T, Wesemann DR, Harkins LE, Van Meir EG and Samanta M (2004). Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells. Cancer Res 63, 8670-73
Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH, Kaur B, Devi SN and Van Meir EG (2004). Pseudopalisading cells in glioblastoma are hypoxic and likely represent an actively migrating population Cancer Res (in press Feb issue)
Yang L, Cao Z, Li F, Post DE, Van Meir EG, Zhong H and Wood WC (2004). Tumor-specific gene expression using the Survivin promoter is further increased by hypoxia Gene Therapy 11, 1215-23 IF: (4.8); cit: 19
Koivisto PA, Zhang X, Sallinen S-L, Sallinen P , Helin HJ, Dong J-T, Van Meir EG, Haapasalo H, Hyytinen E-R, (2004) Absence of KLF6 Gene Mutations in Human Astrocytic Tumors and Cell Lines (letter) Int J Cancer 111, 642-643 IF: (4.7); cit: 4
Ahn J-Y., Rong R, Todd G. Kroll TG, Kalman D, Van Meir EG, Snyder SH and Ye K (2004) PIKE-A GTPase Stimulates Akt Activity and Mediates Cellular Invasion J Biol Chem 279, 16441-16451 IF: (7.0); cit: 13
Stone A, Bobo W, Brat DJ, Devi SN, Van Meir EG and Vertino PM (2004) Aberrant methylation and downregulation of TMS1 in human glioblastoma multiforme Am J Pathol 165, 1151-1161 IF: (5.7): cit: 9
Landen JW, Hau V, Wang M, Davis T, Ciliax B, Wainer B, Van Meir EG, Glass D, Joshi HC and Archer DR (2004) Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth Clin Cancer Res 10, 5187-5201 IF: (5.7); cit: 7
Post DE, Devi NS, Li Z, Brat DJ, Kaur B, Nicholson A, Olson JJ, Zhang Z and Van Meir EG (2004) Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res 10, 8603-8612 IF: (5.7); cit: 10
Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z, Zhang H, Teng Q, Nicholson AC, Giannakakou P, Zhou W, Olson JJ, Pereira MM, Nicolaou KC, and Van Meir EG (2005) Identification of a novel small molecule inhibitor of the hypoxia-inducible factor-1 (HIF-1) pathway. Cancer Res 65, 605-612 IF: (7.6); cit: 29 Featured in the Highlight section and on the journal cover best poster award at 2004 Georgia Life Science Summit
Nicholson AC, Malik S-B, Logsdon JM and Van Meir EG (2005) Functional evolution of ADAMTS genes: evidence from analyses of phylogeny and gene organization BMC Evol Biol 5, 11-23 IF: (4.4); cit: 11
Kaur B, Brat DJ, Devi SN, and Van Meir EG (2005) Vasculostatin, a natural proteolytic fragment of brain angiogenesis inhibitor 1 is an anti-angiogenic and anti-tumorigenic factor Oncogene 24, 3632-3642 IF: (6.8); cit: 9 Georgia Life Science Summit award
Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG and Brat DJ (2005) PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma Cancer Res 65, 1406-1413 IF: (7.6); cit: 17
Li YC, Tzeng CC, Song JH, Tsia FJ, Hsieh LJ, Liao SJ, Tsai CH, Van Meir EG, Hao C and Lin CC (2006) Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with TRAIL and chemotherapy Clin Cancer Res 12, 2716-2729 IF: (5.7); cit: 0
Khwaja FW, Larkin Nolen JD, Mendrinos SE, Lewis MM, Olson JJ, Pohl J, Van Meir EG, Ritchie JC, Brat DJ (2006) Proteomic analysis of cerebrospinal fluid discriminates malignant and non-malignant disease of the central nervous system and identifies specific protein markers Proteomics 6, 6277-6287 IF: (6.0); cit: 0
Rong Y, Hu F, Huang RP, Mackman N, Horowitz JM, Jensen RL, Durden DL, Van Meir EG and Brat DJ (2006) Egr-1 regulates hypoxia-induced expression of tissue factor in glioblastoma through HIF-1 independent mechanisms Cancer Res 66, 7067-74 IF: (7.6); cit:0
Kang SH, Cho H, Devi SN, Zhang Z, Escuin D, Liang Z, Mao H, Brat DJ, Olson JJ, Simons JW, LaVallee TM, Giannakakou P, Van Meir EG, Shim H (2006) Anti-tumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model Cancer Res 66, 11991-11997 IF: (7.6); cit:0 Press release
Khwaja FW, Duke-Cohan JS, Brat DJ, and Van Meir EG (2006) Attractin is elevated in the cerebrospinal fluid (CSF) of patients with malignant astrocytoma and mediates glioma cell migration Clin Cancer Res 12, 6331-6336 IF: (5.7); cit: 2 Press release
Khwaja FW, Svoboda P, Reed MS, Pyrzynska B, Pohl J and Van Meir EG (2006) Proteomic identification of the WT-p53 regulated tumor cell secretome Oncogene 25, 7650-7661 IF: (6.8); cit: 0 Press release
Khwaja FW, Reed MS, Olson JJ, Schmotzer BJ, Gillespie GY, Guha A, Groves MD, Kesari S, Pohl J and Van Meir EG (2007) Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res 6, 559-570 IF: (6.9); cit: 0 best poster award at 2006 Georgia Life Science Summit best translational poster at WCI 2006 annual symposium Press release
Post DE, Sandberg EM, Devi SN, Brat DJ, Xu Z, Tighiouart M and Van Meir EG (2007) Targeted cancer-gene therapy using a HIF-dependent oncolytic adenovirus armed with interleukin-4 Cancer Res 67, 6872-81 IF: (7.6); cit: 0
Boulay JL, Miserez AR, Zweifel C, Sivasakaran B, Kana V, Ghaffari A, Luyken C, Sabel M, Zerrouqi A, Wasner M, Van Meir EG, Tolnay M, Reifenberger G and Merlo A (2007) Loss of Notch2 positively predicts survival in distinct subgroups of human oligodendroglioma and glioblastoma PloS ONE 6, e576 IF: (); cit: Press release
Kim H-S, Peng G-Y, Hicks J, Van Meir EG, Brenner MK and Yotnda P (2008) Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment Molecular Therapy (in press) IF: (5.8); cit:
Ventii KH, Devi NS, Friedrich KL, Chernova T, Tighiouart M, Van Meir EG, Wilkinson KD (2008) BAP1 (BRCA1-associated Protein 1) is a tumor suppressor that requires deubiquinating activity and nuclear localization Cancer Res 68, 6953-62 IF: (7.6); cit: 0
The Cancer Genome Atlas Research Network; McLendon R, Friedman A, Bigner D, Van Meir EG, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-8 IF: (28); cit:
Kaur B, Cork S, Sandberg E, Devi NS, Zhang Z, Klenotic PA, Febbraio M, Shim HS, Mao H, Tucker-Burden C, Silverstein RL, Brat DJ, Olson J and Van Meir EG (2009) Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism Cancer Res (in press) IF: (7.7); cit: best poster awards at 2005 and 2008 Georgia Life Science Summit
Dasgupta A, Raychaudhuri B, Haqqi T, Prayson R, Van Meir EG, Vogelbaum M and Haque SJ (2008) Stat3 Activation Is Required for the Progression of the Growth of Glioblastoma Multiforme Eur J Cancer 45, 677-84
Kaur B, Cork S, Sandberg E, Devi NS, Zhang Z, Klenotic PA, Febbraio M, Shim HS, Mao H, Tucker-Burden C, Silverstein RL, Brat DJ, Olson J and Van Meir EG (2009) Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism Cancer Res 69, 1212-20
Best poster awards at 2005 and 2008 Georgia Life Science Summit;
Featured in the March 2009 issue of the NAVBO Vascular Biology Publications Alert
Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Jeffrey J Olson, Van Meir EG, Mackman N and Brat DJ (2009) EGFR and PTEN modulate tissue factor expression in glioblastoma through JunD/AP-1 transcriptional activity Cancer Res 69, 2540-49
Narita T, Yin S, Gelin CF, Moreno CS, Yepes M, Nicolaou KC and Van Meir EG. Identification of a novel small molecule HIF-1a translation inhibitor (2009) Clin Cancer Res
Klenotic PA, Huang P, Palomo J, Kaur B, Van Meir EG, Vogelbaum MA, Febbraio M, Gladson CL and Silverstein RL. Histidine-rich glycoprotein modulates the anti-angiogenic effects of Vasculostatin (2010) Am J Pathol
Review Articles
Takeshima H, Sawamura Y, Gilbert MR and Van Meir EG (2000). Application of advances in molecular biology to the treatment of brain tumors. Current Oncol. Report 2, 425-433
Brat D and Van Meir EG (2001). Glomeruloid microvascular proliferation orchestrated by VPF/VEGF. A new world of angiogenesis research. Am. J. Pathol. 158, 789-796
de Fraipont F, Nicholson A, Feige JJ and Van Meir EG (2001). The Thrombospondin family of extracellular matrix proteins: potent inhibitors of tumor angiogenesis. Trends Mol. Medicine 7, 401-407
Brat DJ, Castellano-Sanchez A, Kaur B and Van Meir EG (2002). Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv. Anat. Pathol. 9, 24-36
Brat DJ, Kaur B and Van Meir EG (2002). Genetic modulation of hypoxia-induced gene expression and vascular proliferation: relevance to brain tumors. Front. Biosci. 8, d100-116
Post D.E, Khuri F, Simons JW and Van Meir EG (2003). Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum. Gene Ther. 14, 933-946
Hunter SB, Brat DJ, Olson JJ, von Deimling A, Zhou W and Van Meir EG (2003). Alterations in molecular pathways of diffusely infiltrating glial neoplasms; application to tumor classification and anti-tumor therapy. Int J Oncol 23, 857-869
Post D.E, Fulci G, Chiocca EA, and Van Meir EG (2004). Replicative oncolytic herpes simplex viruses in combination cancer therapies. Current Gene Therapy
Bellail A, Hunter S, Brat DJ and Van Meir EG (2004). Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int. J. Biochem. & Cell Biol.
Brat DJ and Van Meir EG (2004). Vaso-occlusive and pro-thrombotic mechanisms associated with tumor hypoxia,, necrosis and accelerated growth in glioblastoma. Lab Invest
Van Meir EG, Bellail A and Phuphanich S (2004) Emerging molecular therapies for brain tumors. Semin Oncol 31, 38-46 IF: (3.6); cit: 8
Chu R, Post D.E, Khuri F and Van Meir EG (2004). Use of replicative oncolytic adenoviruses in combination therapy for cancer Clin Cancer Res 10, 5299-5312 IF: (5.7); cit: 21
Kaur B, Tan C, Brat DJ and Van Meir EG (2004) Genetic and hypoxic regulation of angiogenesis in gliomas J Neuro-Oncol 70, 229-243 IF: (2.3); cit: 16
Brat DJ, Bellail A, and Van Meir EG (2005) The role of Interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis Neuro-Oncol 7, 122-133 IF: (4.1); cit: 23
5th most frequently read article in Neuro-Oncology (May 2006 ranking)
Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, and Van Meir EG (2005) Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-Oncol 7, 134-153 IF: (4.1); cit: 17 Most frequently read article in Neuro-Oncology (May 2006 ranking)
Post DE, Shim HS, Toussaint-Smith E and Van Meir EG (2005) Cancer Scene Investigation: how a cold virus became a cancer killer Future Oncology 1, 247-258 IF: (n/a); cit: 0
Belozerov V and Van Meir EG (2005) Hypoxia Inducible factor-1: a novel target for cancer therapy Anti-Cancer Drugs 16, 901-909 IF: (1.9); cit: 13
Rong Y, Durden DL, Van Meir EG and Brat DJ (2006) "Pseudopalisading" necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia and angiogenesis J Neuropathol Exp Neurol 65, 529-539 IF: (4.4); cit: 0
Belozerov V and Van Meir EG (2006) Inhibitors of Hypoxia Inducible Factor-1 signaling Current Opinion in Investigational Drugs 7, 1067-1076 IF: (n/a); cit: 0
Hadjipanayis CG and Van Meir EG (2009) Tumor initiating cells in malignant gliomas: biology and implications for therapy J Mol Medicine 87, 363-374
Hadjipanayis CG and Van Meir EG (2009) Brain tumor stem cells: biology, genetics, and targeted therapies Trends Mol Medicine 15, 519-30
Van Meir EG, Hadjipanayis C, Norden AD, Wen PY, Shu HK and JJ Olson (2010) Recent advances in neuro-oncology: new therapeutic approaches for malignant glioma CA Cancer J Clin (in press)
Symposium Contributions
Van Meir EG and de Tribolet N (1991). "Immunbiologie und Immuntherapie der Gliome" (in German). in Verhandlungen der Deutschen Gesellschaft fur Neurologie. Firnhaber, W., Dworschak, K., Lauer, K., Nichtweiss, M., eds., Springer Verlag (Berlin), 6, 410-415.
Books
CHAPTERS:
Rosenblum MK, Matsutani M, and Van Meir EG (2000). Central nervous system germ cell tumors. In Tumors of the Nervous System. Kleihues, P. and Cavenee, W.K. (eds.), World Health Organization Classification of Tumors, International Agency for Research on Cancer, Lyon p.207-214
Cavenee WK, Burger PC and Van Meir EG (2000). Turcot syndrome. In Tumors of the Nervous System. Kleihues, P. and Cavenee, W.K. (eds.), World Health Organization Classification of Tumors, International Agency for Research on Cancer, Lyon p.238-239
Van Meir EG, Hao C, Post DE, Liau L and Brat DJ (2003). Therapeutic targeting of molecular pathways that induce brain tumor development. In Genomic and Molecular Neuro-Oncology. Zhang W. and Fuller GN (eds.) Jones and Bartlett Publishers Inc. p.303-331
Dey, N, Durden DL and Van Meir EG (2006) Cytokine expression and signaling in CNS tumors. In Cytokines and the CNS II. Benveniste EN and Ransohoff RM (eds) CRC Press. p.193-242.
Cavenee WK, Burger PC, Leung SY and Van Meir EG (2007) Turcot syndrome. In WHO Classification of Tumors of the Central Nervous System. Louis D, Ohgaki H, Wiestler O and Cavenee, W.K. (eds.), International Agency for Research on Cancer, Lyon p.229-231
Khwaja FW and Van Meir EG (2009) Past, present and future of proteomics for CNS tumors In CNS cancer: Models, Prognostic Factors and Targets, Van Meir EG (ed.) Humana Press, Springer
Post DE and Van Meir EG (2009) The development of targeted cancer therapy adenoviruses for malignant glioma treatment In CNS cancer: Models, Prognostic Factors and Targets, Van Meir EG (ed.) Humana Press, Springer
Yin S and Van Meir EG (2009) The p53 pathway in CNS tumors In CNS cancer: Models, Prognostic Factors and Targets, Van Meir EG (ed.) Humana Press, Springer
BOOK REVIEWS:
Van Meir EG (1997) Cytokines and the CNS (book review) Chem Neuroanat 13, 141-144.
BOOK EDITOR:
CNS Cancer: Models, Prognostic Factors and Targets., Erwin G Van Meir, Editor Humana Press (Springer) In Progress-2009 print date. Cancer Drug Discovery and Development series, Dr. Beverly Teicher, series Editor
Other Publications
Van Meir EG (2003) Lifeline. The Lancet 361, 1234 IF: (28.6)
Van Meir EG (2003) Interview in brochure from The Brain Tumor Society. Heads-up 14, 1-3
Van Meir EG (2004) Opening the chamber of peer-review secrets (correspondence) Nature 429, 803 IF: (28.8)
Van Meir EG (2005) Biography featured on journal cover Int J Oncology 26, 1447 IF: (2.3)
Van Meir EG (2007) Interview in brochure from The National Brain Tumor Foundation. Search 70, 4
Co-signatory in Aitman et al (2008) IF: (25.6) Progress and prospects in rat genetics: a community perspective Nature Genetics 40, 516-22
Van Meir EG, Lavanchy D, and Moss B (2009) In Memoriam: Riccardo (Rico) Wittek (1944-2008) J Virology 70, 4
Hentschel G, Family F, Van Meir EG, Grossniklaus H (2010) Hybrid cellular continuum simulations of heterogeneity in tumor growth Bull Am Phys Soc 55 (abstract)
Consulted for Science-Business Exchange (SciBX, Nature publisher), Tim Fulmer Senior writer Fulmer, T. (2010) Targeting chemokines in breast cancer SciBX 3(4); doi:10.1038/scibx.2010.105 Published online Jan. 28, 2010
100+ conference abstracts
Manuals, videos, computer programs, media relations and other teaching aids:
Research on p53 secretome featured in Science Daily (Oct 27, 2006)
http://www.sciencedaily.com/releases/2006/10/061025180249.htm
Research on p53 secretome featured in Medical News Today (Oct 28, 2006)
http://www.medicalnewstoday.com/medicalnews.php?newsid=55141
Research on p53 secretome featured in Emory Report (Oct 30, 2006)
http://www.emory.edu/EMORY_REPORT/erarchive/2006/October/October%2030/SandRWinship.htm
Research on attractin featured in SAWF NEWS (Nov 10, 2006)
http://news.sawf.org/Health/26788.aspx
Research on attractin featured in bio.com (Nov 10, 2006)
http://www.bio.com/newsfeatures/newsfeatures_research.jhtml?cid=23500019
Research on attractin featured in Virtual trials (Nov 11, 2006)
http://virtualtrials.com/news3.cfm?item=3707
Research on attractin featured in Medical News Today (Nov 11, 2006)
http://www.medicalnewstoday.com/medicalnews.php?newsid=56389
Research on attractin featured in Science Daily (Nov 13, 2006)
http://www.sciencedaily.com/releases/2006/11/061112094644.htm
Research on attractin featured in Playfuls (Nov 16, 2006)
http://www.playfuls.com/news_002946_Biomarker_Detects_Regulates_Brain_Tumors.html
Research on attractin featured in Physorg (Nov 16, 2006)
http://www.physorg.com/news82923017.html
Research on attractin featured in Dental Plans (Nov 16, 2006)
http://www.dentalplans.com/articles/5997/
Research on attractin featured in HealthNewsDigest (Nov 17, 2006)
http://healthnewsdigest.com/news/article_4795.shtml
Research on attractin featured in Emory Report (Nov 27, 2006)
http://www.emory.edu/EMORY_REPORT/erarchive/2006/November/November%2027/S&RBiomarker.htm
Research on attractin featured in Cancer Weekly (Dec 5, 2006)
http://www.newsrx.com/cgi-bin/samplepdf.cgi?filename=cw.pdf Research on attractin featured in World News
http://1-news.org/world-news/Newly-Identified-Biomarker-Detects-and-Regulates-Spread-of-Brain-Tumors/
Research on attractin featured in Science News Den (Dec 2006)
http://www.sciencenewsden.com/2006/newlyidentifiedbiomarkerdetectsandregulatesspreadofbraintumors.shtml
Research on attractin featured in CprMap
http://www.cprmap.com/faq.php
Research on attractin featured in DRIC (drug research information center)
http://dric.sookmyung.ac.kr/trend/recent_news_detail.html?id=258
Research on attractin featured in Bioguider
http://www.bioguider.com/en/news/Neurosci/200611/24722.shtml
Research on attractin featured in Bioon
http://www.bioon.com/biology/Class18/242794.shtml
Research on attractin featured in Iconoclast
http://www.iconocast.com/News_Files/A1SW0/News7.htm
Research on 2ME2 featured in Yahoo Finance
http://biz.yahoo.com/prnews/061221/dcth009.html?.v=76
Press release on research on new markers in the CSF of brain tumor patients
http://whsc.emory.edu/press_releases2.cfm?announcement_id_seq=8900
Research on new markers in the CSF of brain tumor patients featured in Emory Report
http://www.emory.edu/EMORY_REPORT/erarchive/2007/February/February%205/research_roundup.htm
Research on new markers in the CSF of brain tumor patients featured in Health Orbit
http://healthorbit.ca/NewsDetail.asp?opt=1&nltid=096290107
Research on Notch2 featured in Science Daily (June 27, 2007)
http://www.sciencedaily.com/releases/2007/06/070627091626.htm
Research on Galectin-3 featured in Atlanta Business Chronicle and Dekalb Neighbor (2008)
http://virtualtrials.com/news3.cfm?item=4295
Interviewed for Emory Magazine, Automn 2008 issue
http://www.emory.edu/EMORY_MAGAZINE/2008/autumn/tumors.html
Interviewed for Working Mom Magazine by Romina Tobias, ABS-CBN Publishing, October 2008 issue, Brain tumors and cell phone use
Research on vasculostatin featured in EMORY Report, Feb 23, 2009 issue
http://www.emory.edu/EMORY_REPORT/pdf/ER_Feb.23.09_web.pdf
Research on small molecule HIF inhibitor KC7F2 featured in HealthNewsDigest, Sep 30, 2009
http://www.healthnewsdigest.com/news/Cancer_Issues_660/Potential_Drug_Kills_Cancer_Cells_by_Preventing_Response_to_Low_Oxygen.shtml
Research on small molecule HIF inhibitor KC7F2 featured in Insciences Organisation, Oct 1, 2009
http://insciences.org/article.php?article_id=6993
Research on small molecule HIF inhibitor KC7F2 featured in Futurity, March 2, 2010
http://futurity.org/health-medicine/drug-may-help-suffocate-cancer-cells/#more-4620
